SOUTH SAN FRANCISCO, Calif. – Fluidigm Corporation (NASDAQ:FLDM) today announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 833,750 shares of Fluidigm common stock at $13.50 per share, less underwriting discounts and commissions.

Together with the shares sold pursuant to the over-allotment option, Fluidigm has sold a total of 6,392,083 shares of common stock in its initial public offering, with net proceeds to Fluidigm of $78.0 million, after deducting underwriting discounts and commissions and expenses payable by the company.

Deutsche Bank Securities Inc. and Piper Jaffray & Co. acted as joint book-running managers for the offering, and Cowen and Company LLC and Leerink Swann LLC acted as co-managers.

A registration statement relating to the offering was declared effective by the Securities and Exchange Commission on February 9, 2011. This offering is being made solely by means of a prospectus, copies of which may be obtained from: Deutsche Bank Securities Inc., Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, or by calling (800) 503-4611 or emailing a request to [email protected] or by contacting Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, by calling 1-800-747-3924.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Fluidigm

Fluidigm develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including chips and reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems including eight different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions, diagnostic laboratories and Ag-Bio companies.

For more information, please visit www.fluidigm.com.